REDEFINE-4

Head-to-head clinical trial comparing CagriSema with tirzepatide 15 mg over 84 weeks (-23.0% versus -25.5%), in which CagriSema failed to meet its non-inferiority endpoint.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.